Supply Agreement For Api

Processing the Batch API for batch, month after month, year after year, can lead over time to complacency and problems related to the status quo in processes, processes, and technologies. If the manufacturer of low molecular active ingredients you have chosen does not constantly focus on continuous process improvement, it may not be the ideal partner for the strategic supply of medicines. (b) In the event of any disagreement between the parties as to the compliance of the Bulk Substance API with the applicable specifications, the parties` quality assurance representatives will discuss in good faith to attempt to resolve such disagreement, and the customer and Pfizer will follow their respective standard working instructions to determine the bulk Drug Substance API`s compliance with the specifications. If the above discussions do not resolve the disagreement within a reasonable period of time (which will not exceed [**], a sample of the USFDA sample retained by Pfizer and a sample of the relevant bulk API drug substance will be submitted for re-testing by Pfizer and customers, to definitively determine whether this API bulk substance complies with the specifications. Such re-testing shall be performed in a laboratory designated by the Customer and approved by Pfizer, using the test methods referred to in the specifications of this Agreement and with representatives of both Parties present at all repeat tests. The determination of compliance or non-compliance by such a new test concerning all or part of this Bulk Drug Substance API is final and binding on the parties. The costs of such a new test shall be borne by Pfizer if the test confirms the non-conformity and, failing that, by the customer if the test confirms compliance. (a) First prognosis. Upon completion of this delivery agreement, Customer will provide Pfizer with Customer`s good faith estimate of Customer`s anticipated needs for delivery of API Bulk Drug Substance for delivery during the first [***] (such estimate, the “Initial Supply Forecast”).

The first [***] of the initial delivery forecast is mandatory and the customer must place an order in accordance with section 2.02 for this first [**] of the first current delivery forecast. The following [***] of this initial delivery forecast is a binding obligation in which the customer may not change the quantities of more than [**] in any month. The last [***] of this first supply forecast is a good faith estimate provided exclusively to assist Pfizer in production planning. (g) Pfizer will make economically reasonable efforts to deal with changes to orders that Customer may request after receipt and acceptance by Pfizer, but is not responsible for its failure to do so. Orders may be modified by mutual agreement between the parties. March 10: In response to the COVID-19 outbreak, the FDA updated the status of FDA inspections outside the United States. The FDA trusts most foreign inspections until April with immediate effect. Inspections outside the United States, deemed critical to the cases, continue to be considered on a case-by-case basis. The FDA based this decision on State Department Level 4 travel instructions banning travel for U.S. government employees, CDC and Prevention travel recommendations, access restrictions imposed on foreign visitors by certain countries, and guidelines from the Office of Personnel Management. According to the FDA, it remains confident in its ability to maintain oversight of international manufacturers and imported products using alternative tools and methods. If they are unable to physically inspect foreign-made FDA products or manufacturers, additional tools will be used to ensure the safety of products imported into the United States, including: refusal to import dangerous products into the United States, physical examinations and/or samples of products at our borders, verification of a company`s previous compliance history, the use of information exchange by foreign governments in the context of mutual recognition and confidentiality agreements and the requirement for registration “before or at the place of on-site drug control.

. . .

Comments are closed.